Non‐Vitamin K Antagonist Oral Anticoagulants Provide Less Adverse Renal Outcomes Than Warfarin In Non‐Valvular Atrial Fibrillation: A Systematic Review and MetaAnalysis
Background Non‐vitamin K antagonist oral anticoagulants (NOACs) have better pharmacologic properties than warfarin and are recommended in preference to warfarin in most patients with non‐valvular atrial fibrillation. Besides lower bleeding complications, other advantages of NOACs over warfarin parti...
Main Authors: | Patita Sitticharoenchai, Kullaya Takkavatakarn, Smonporn Boonyaratavej, Kearkiat Praditpornsilpa, Somchai Eiam‐Ong, Paweena Susantitaphong |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2021-04-01
|
Series: | Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease |
Subjects: | |
Online Access: | https://www.ahajournals.org/doi/10.1161/JAHA.120.019609 |
Similar Items
-
Comparing clinical outcomes of NOACs with warfarin on atrial fibrillation with Valvular heart diseases: a meta-analysis
by: Qiyu He, et al.
Published: (2019-05-01) -
Anticoagulation in Patients with End-Stage Renal Disease and Non-Valvular Atrial Fibrillation – Review Article
by: Mahmoud Khalifa, et al.
Published: (2021-05-01) -
Risk of Ischemic Bowel Disease in Patients With Atrial Fibrillation Receiving Warfarin or Non-vitamin K Antagonist Oral Anticoagulants
by: Jo-Nan Liao, et al.
Published: (2022-07-01) -
Long-term stroke and major bleeding risk in patients with non-valvular atrial fibrillation: A comparative analysis between non-vitamin K antagonist oral anticoagulants and warfarin using a clinical data warehouse
by: Hancheol Lee, et al.
Published: (2023-01-01) -
Comparative effectiveness of rivaroxaban versus warfarin or dabigatran for the treatment of patients with non-valvular atrial fibrillation
by: Faye L. Norby, et al.
Published: (2017-09-01)